Zin is an Associate at the International Unit of the Health Intervention and Technology Assessment Program (HITAP) Foundation. She specializes in Health Technology Assessment (HTA) to inform decision making in health policy through country-focused initiatives. Zin received her Bachelor in Pharmacy from University of Pharmacy (Yangon) and completed

Chayapat Rachatan is currently a Project Associate at HITAP. She supports the HTA and health system research. Her research studies focus on COVID-19 policy research and decision support, effectiveness evaluation of COVID-19 vaccine chatbot, cost analysis of governance system in health sector, situational analysis of infectious disease modelling in

Saudamini Dabak is the Head of HITAP’s International Unit (HIU). She started working at HITAP as an Overseas Development Institute (ODI) Fellow in 2015. At HITAP, Saudamini has supported Health Technology Assessment (HTA) initiatives in Asia and Africa and has also been involved in conducting health systems research. Prior to working at HITAP, Saud

Parntip Juntama is a Researcher at HITAP specializing in Health Technology Assessment (HTA) and Health Economics. Her work focuses on policy-related research that provides evidence to support healthcare policy decisions in Thailand.Research Focus:Parntip conducts research on various health policy topics to inform national public health strategies.

Picharee Karunayawong is a researcher and economist at the Health Intervention and Technology Assessment Program Foundation (HITAP). Her work focuses on data-driven and quantitative research aimed at improving the efficiency of national health systems and reducing the use of low-value care. She works closely with the policymakers, participating in

Yot Teerawattananon is a Assistant Secretary General of the Foundation & Senior Researcher of the Health Intervention and Technology Assessment Program (HITAP), which is a semi-autonomous research institute of Thailand’s Ministry of Public Health. The works of HITAP have been used to inform policy decisions regarding the adoption of medicines,

Dr. Wanrudee Isaranuwatchai is a Secretary General and Senior Researcher of the Health Intervention and Technology Assessment Program Foundation (HITAP), Thailand. She is also an Affiliated Scientist at St. Michael’s Hospital, and an Associate Professor at the Institute of Health Policy, Management and Evaluation, University of Toronto, in Canada.H

Management of advanced prostate cancer, particularly in cases of metastatic castration-resistant prostate cancer (mCRPC), typically involves first-line treatment with the chemotherapeutic agent docetaxel. Nevertheless, disease progression following docetaxel therapy remains a major challenge, as there are currently no therapeutic options listed in

COVID-19 has shown that irresepctive of national borders, the infectious disease brings multi-dimensional challenges requiring concerted global and regional efforts to address it. In contrast to the European Union and the African Union, the Association of Southeast Asian Nations (ASEAN), the regional cooperation body in Southeast Asia, has had no e

COVID-19 has shown that irresepctive of national borders, the infectious disease brings multi-dimensional challenges requiring concerted global and regional efforts to address it. In contrast to the European Union and the African Union, the Association of Southeast Asian Nations (ASEAN), the regional cooperation body in Southeast Asia, has had no e